相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single-center retrospective study in Japan
Masaki Otsuka et al.
JOURNAL OF DERMATOLOGY (2020)
Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer
Teppei Sugano et al.
THORACIC CANCER (2020)
Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
Xiaoxiang Zhou et al.
BMC MEDICINE (2020)
Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis
Doran Ksienski et al.
CLINICAL LUNG CANCER (2019)
Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients
J. Rogado et al.
EUROPEAN JOURNAL OF CANCER (2019)
Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients.
Roy Elias et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study
Birgitte Bjornhart et al.
ACTA ONCOLOGICA (2019)
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
V. Ellen Maher et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Elena Verzoni et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients
Taketo Kawai et al.
EUROPEAN JOURNAL OF CANCER (2019)
High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients
Dedong Cao et al.
ONCOIMMUNOLOGY (2019)
Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer - a retrospective multicentre study
Isaku Okamoto et al.
ACTA OTO-LARYNGOLOGICA (2019)
High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer
Mari Tone et al.
THORACIC CANCER (2019)
The association of PD-L1 expression with the efficacy of antiPD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials
Yangyang Xu et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
Ken Masuda et al.
BMC CANCER (2019)
Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma
Hamzah Abu-Sbeih et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer
Mathieu Grangeon et al.
CLINICAL LUNG CANCER (2019)
Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study
Naoto Okada et al.
CLINICAL THERAPEUTICS (2019)
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
Biagio Ricciuti et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma
Alice Indini et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash
Pradnya D. Patil et al.
ONCOLOGIST (2019)
Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients
Michael D. Richter et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer
Yukihiro Toi et al.
JAMA ONCOLOGY (2019)
Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer
Hye In Kim et al.
ONCOIMMUNOLOGY (2018)
Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study
Charles Kyung Min Lee et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
Koichi Sato et al.
LUNG CANCER (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center
Aaron Lisberg et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer
Koji Haratani et al.
JAMA ONCOLOGY (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer
Dwight H. Owen et al.
CLINICAL LUNG CANCER (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC
Paul Lesueur et al.
CANCER MEDICINE (2018)
Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy
Hammad Shafqat et al.
SEMINARS IN ONCOLOGY (2018)
Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody
Koung Jin Suh et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
J. C. Osorio et al.
ANNALS OF ONCOLOGY (2017)
Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study
Yasuhiro Nakamura et al.
JOURNAL OF DERMATOLOGY (2017)
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
Shunsuke Teraoka et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors
Julia Judd et al.
ONCOLOGIST (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials
B. El Osta et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
N. Chaput et al.
ANNALS OF ONCOLOGY (2017)
Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study
Naoya Yamazaki et al.
CANCER SCIENCE (2017)
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
Morganna Freeman-Keller et al.
CLINICAL CANCER RESEARCH (2016)
Use of LDH and autoimmune side effects to predict response to ipilimumab treatment
J. Dick et al.
IMMUNOTHERAPY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Krista Dubin et al.
NATURE COMMUNICATIONS (2016)
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
Yoshio Nakamura et al.
ONCOTARGET (2016)
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
Camille Hua et al.
JAMA DERMATOLOGY (2016)
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
Hansje-Eva Teulings et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical Development of Immune Checkpoint Inhibitors
Ayumu Ito et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Martina Sanlorenzo et al.
JAMA DERMATOLOGY (2015)
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
Taku Okazaki et al.
NATURE IMMUNOLOGY (2013)
Evaluation of the Endorsement of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement on the Quality of Published Systematic Review and Meta-Analyses
Nikola Panic et al.
PLOS ONE (2013)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
Immunostimulatory monoclonal antibodies for cancer therapy
Ignacio Melero et al.
NATURE REVIEWS CANCER (2007)
Autoimmune aspects of depigmentation in vitiligo
IC Le Poole et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2004)
Meta-analysis of observational studies in epidemiology - A proposal for reporting
DF Stroup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
分享论文
